Polyunsaturated fatty acids in atrial fibrillation: looking for the proper candidates

Oscar Salvador-Montañés 1, Alfonso Gómez-Gallanti 1, Daniel Garofalo 1, Sami F. Noujaim 2, Rafael Peinado 1 and David Filgueiras-Rama 1*

1 Cardiac Electrophysiology Unit, Department of Cardiology, Hospital Universitario la Paz, Madrid, Spain
2 Department of Internal Medicine, Center for Arrhythmia Research, University of Michigan, Ann Arbor, MI, USA

*Correspondence:
David Filgueiras-Rama, Cardiac Electrophysiology Unit, Department of Cardiology, Hospital Universitario la Paz, Paseo de la Castellana 261, 1st floor, 28046 Madrid, Spain. e-mail: david.filgueiras@salud.madrid.org

Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in clinical practice with growing prevalence in developed countries. Several medical and interventional therapies, such as atrial specific drugs and pulmonary vein isolation, have demonstrated prevention of recurrences. However, their suboptimal long-term success and significant rate of secondary effects have led to intensive research in the last decade focused on novel alternative and supplemental therapies. One such candidate is polyunsaturated fatty acids (PUFAs). Because of their biological properties, safety, simplicity, and relatively cheap cost, there is a special clinical interest in omega-3 PUFAs as a possible antiarrhythmic agent. Obtained from diets rich in fish, they represent one of the current supplemental therapies. At the cellular level, an increasing body of evidence has shown that n-3 PUFAs exert a variety of effects on cardiac ion channels, membrane dynamic properties, inflammatory cascade, and other targets related to AF prevention. In this article, we review the current basic and clinical evidence pertinent to n-3 PUFAs in AF treatment and prevention. We also discuss controversial outcomes among clinical studies and propose specific subsets of AF patients who will benefit most from n-3 PUFAs.

Keywords: atrial fibrillation, omega-3 polyunsaturated fatty acids, remodeling, prevention, drug therapy
long hydrocarbon chain of the n-3/n-6 PUFAs, with multiple double bonds and with the first double bond occurring in the C3/C6 position result in complex and unique 3-dimensional configurations of PUFAs that are essential to their biological properties (Mozaffarian and Wu, 2011).

Fatty acids required for normal physiological functions that are produced by the body but obtained from food are called essential. Two of these are linoleic (n-6 PUFA) and α-linolenic (n-3 PUFA) acids. Once ingested, biochemical pathways can further metabolize essential fatty acids into long-chain more unsaturated derivatives. Linoleic acid can be converted into arachidonic acid and α-linolenic acid into eicosapentaenoic and docosahexaenoic acids (EPA and DHA, respectively; Burdge et al., 2002). However, endogenous conversion is very limited in humans (80% assuming the best scenario), which makes tissue and circulating EPA and DHA levels primarily dependent on direct dietary consumption (Burdge, 2004). While plants are a good source of linoleic and α-linolenic acids, longer chain n-3 fatty acids are mainly obtained from fish (tuna, herring, mackerel, etc.). In humans, fish oil supplements result in progressively higher proportions of EPA, DHA, and total n-3 PUFAs in atrial phospholipids, along with a reciprocal lowering of long-chain n-6 PUFAs, predominantly arachidonic acid (Metcalfe et al., 2007). Animal and human studies demonstrate a progressive incorporation of n-3 PUFAs in the myocardial cell membrane over a 30-day period (Owen et al., 2004; Metcalf et al., 2004). Certain factors such as age, diabetes, body mass index, etc. could affect the incorporation of n-3 PUFAs into the cell membrane (Sands et al., 2005). Therefore, the slow and gradual incorporation of n-3 PUFAs into the membrane phospholipids should be taken into consideration when assessing the beneficial effects of PUFAs supplemental therapy, since a delay in protection can be expected. This has been observed when prevention of total mortality and sudden cardiac death was examined after the initiation of n-3 PUFA supplementation (Marchioli et al., 2002). Similarly, diverging results on the rate of recurrences after a DC shock in patients with persistent AF may also be partially explained by differences in the duration of n-3 PUFA therapy before cardioversion (Bianconi et al., 2011; Nodari et al., 2011).

**CELLULAR EFFECTS OF POLYUNSATURATED FATTY ACIDS**

A large body of evidence supports the role of n-3 PUFAs in stabilizing the cardiomyocyte membrane and altering cardiac cells’ electrophysiology (Leaf et al., 2003). Interestingly, some experiments have demonstrated that n-3 PUFAs exert their effects without strong ionic or covealing binding to specific targets in the cell membrane. It is currently accepted that their incorporation within the hydrophobic tail of the cardiomyocyte membrane phospholipids is sufficient to elicit electrophysiological changes, and even antiarrhythmic action (Kang and Leaf, 1994). However, direct interaction with proteins of certain cardiac ion channels such as Nav1.5 has also been suggested by introducing single amino acid mutations in the wild type protein that significantly reduced the expected potency of EPA to inhibit the fast sodium current (I_{Na}); Xiao et al., 2001).

The effects of PUFAs on cardiac ionic currents have been proposed as a major player in protection against AF. Acute effects of PUFAs on the biophysical properties of ion channels may substantially differ from those of chronically administered PUFAs that are gradually incorporated into the cell membrane (Den Ruijter et al., 2007). In human atrial cells, EPA and DHA acutely inhibit I_{Na} by shifting the potential of I_{Na} availability toward more negative voltages and increasing I_{Na} inactivation at resting states (Li et al., 2009). This effect on I_{Na} has also been observed in HEK 293 cells expressing human cardiac sodium channels and in neonatal rats (Xiao et al., 1995, 1998). In contrast with the acute effects, peak I_{Na} was unaffected by incorporated n-3 PUFAs in ventricular myocytes isolated from pigs and rats fed with a diet rich in fish oil (Leifert et al., 2000; Verkerk et al., 2006).

In addition to affecting I_{Na} the antiarrhythmic properties of PUFAs have also been attributed to their capability to modulate the L-type calcium channel (I_{Ca,L}; Xiao et al., 1997) and the human ether-a-go-go-related gene (HERG) channel, which mediates the repolarizing rapid delayed rectifier K+ current (I_{Kr}; Guizy et al., 2005). Similar to the effects described on I_{Na}, no changes were observed on I_{Kr} density and calcium homeostasis (diastolic Ca2+ and Ca2+ transient amplitude) in pig ventricular myocytes with incorporated sarcolemmal n-3 PUFAs (Verkerk et al., 2006). In the same study and in line with the acute administration (Xiao et al., 2004), chronic administration of n-3 PUFAs resulted in reduced Na+-Ca2+ exchange current (I_{NCX}). This reduction may explain the decreased propensity to develop delayed after depolarizations (Blaustein and Lederer, 1999). Moreover, changes in membrane phospholipids have been observed in rat atrial myocytes after a fish oil dietary supplement compared to saturated and monounsaturated diets. The fish oil dietary supplement was associated with calcium sparks of smaller area, and shorter duration in cells with a higher ratio of n-3 to n-6 PUFAs (Honon and Saint, 2002). This may contribute to prevent diastolic calcium release and decrease the propensity of delayed after depolarizations, which can initiate AF.

With regards to the other repolarizing potassium currents, in human atrial cells, EPA and DHA significantly inhibit the ultra-rapid delayed rectifier K+ current (I_{kur}) and the transient outward K+ current (I_{to}; Li et al., 2009). The inhibition of I_{kur} is of special interest since represents an atrial specific current (Li et al., 1996), and its blockade might lead to AF termination (Blaauw et al., 2004). Although attractive, specific I_{kur}-blockade may not be effective to terminate persistent AF and certain AF models, in which I_{kur} is decreased and increased inward rectifier K+ currents may counterbalance the potential effect of blocking I_{kur} in action potential duration (Van Wagoner et al., 1997; Pandit et al., 2011). Chronic treatment with EPA at low concentrations (1 μM) may increase I_{kur} current. Conversely higher concentrations of DHA and EPA (30 μM; more physiological) decrease the expression of Kv1.5 protein channel (principal molecular component of I_{kur}; Koshida et al., 2009).

In human atrial cells, no significant effects have been recorded in the main inward rectifier potassium current (I_{K1}) after exposing the cells to oleic acid (Grumb et al., 1999). The same results were obtained in ferret cardiomyocytes after acute administration of n-3 PUFAs (Xiao et al., 2002). Conversely, incorporation of n-3 PUFAs into the sarcolemma results in I_{K1} increase by ≈50%, which shortens the action potential duration, reduces delayed after
depolarizations and triggered activity (Verkerk et al., 2006; Den Ruijter et al., 2008). The slow delayed rectifier K+ current (I_{Ks}) also shows significant increase after incorporation of n-3 PUFAs in the sarcolemma of ventricular myocytes (Verkerk et al., 2006). Acute effects on I_{Ks} differ depending on the type of n-3 PUFAs. While DHA has shown to increase I_{Ks} magnitude, EPA does not exert any significant effect on I_{Ks} (Doolan et al., 2002).

Unsaturated free fatty acids such as oleic, linoleic, and arachidonic acids reversibly inhibited the ATP-dependent gating of native acetylcholine-sensitive K+ current (I_{K,ACh}) in rat atrial cells (Kim and Pleumsamran, 2000). Free unsaturated fatty acids of the cardiac cell membrane seem to be crucial to keep the I_{K,ACh} channel in the short-lived, single open state, and maintain low channel activity despite the presence of ATP in the cell. The role of I_{K,ACh} in AF is well described in experimental models of AF. Activation of these channels causes hyperpolarization of the resting membrane potential and shortening of the action potential duration. Heterogeneous distribution of I_{K,ACh} channels in the atria generate non-uniform distribution of refractory periods and make the atria prompt to AF (Moe and Abildskov, 1959; Sarmast et al., 2003).

In addition, n-3 PUFAs might affect stretch activated channels (SAC), which are non-specific ion channels activated in response to mechanical deformation of the membrane. In rat atrial myocytes, membrane compliance increases after acute addition of the n-3 PUFAs DHA and EPA (Jahangiri et al., 2000). Langendorff-perfused hearts of rabbits on a dietary fish oil supplement were more resistant to stretch-induced AF compared to hearts from controls (Ninio et al., 2005). This is similar to the results of earlier experiments (Bode et al., 2001) after blocking SAC by the tarantula venom peptide GsMtx-4. Consequently, it could be speculated that an increase in membrane fluidity could protect against stretch-induced vulnerability to AF. However, it remains unknown whether PUFAs modify the biophysical properties of SAC.

Polynsaturated fatty acids may also act through alternative mechanisms derived from their effects on inflammation, endothelial function, atherosclerosis, etc. Through the activation of transcription factors such as peroxisome proliferator-activated receptors (PPARs) and nuclear factor kappa B (NFkB), n-3 PUFAs are able to regulate metabolism and other cell and tissue responses, such as inflammation. Healthy human volunteers who undertook a dietary fish oil supplement showed decreased production of tumor necrosis factor-α (TNFα), interleukine-1β (IL-1β), IL-6, and various growth factors by monocytes or mononuclear cells that were stimulated with bacterial endotoxin (Endres et al., 1989; Treble et al., 2003). Changes in cell membrane composition after n-3 PUFAs supplementation alter the production and potency of eicosanoid and eicosanoid-like mediators produced from the n-6 PUFAs arachidonic acid (prostaglandins, thromboxanes, and leukotrienes). These have well-established roles in the regulation of inflammation and immunity (Calder, 2006).

Therefore, based on acute effects and incorporation of n-3 PUFAs into the cardiac cell membrane, PUFAs may decrease atrial heterogeneity and Ca^{2+}-induced triggered activity, both leading to lower risk of AF onset and recurrences. Altogether, cellular studies suggest that long-term n-3 PUFAs supplementation may act as an upstream therapy for substrate modification and membrane stabilization rather than a pure antiarrhythmic agent. Summarized acute and chronic n-3 PUFAs effects on cardiac ion currents are shown in Table 1.

**Table 1 | Acute vs. chronic n-3 PUFAs effects or cardiac ion currents.**

| Author/s Year | Ion Current | PUFAs Effects | Cell type |
|---------------|-------------|---------------|-----------|
| Li et al. (2009); Xiao et al. (1995, 1998) | I_{Na} | Decrease | Human atria, HEK 293, neonatal rat ventricular myocytes |
| Leifert et al. (2000); Verkerk et al. (2006) | I_{K} | Unaffected | Pig and rat ventricular myocytes |
| Li et al. (2009) | I_{Cf} | Decrease | Human atria |
| Koshida et al. (2009) | I_{Cf} | Decrease (30µM) | Transfected green monkey kidney fibroblast cells and rat atrium |
| Li et al. (2009) | I_{Ca}L | Decrease | Unknown |
| Xiao et al. (1997) | I_{Ca}L | Decrease | Human atria |
| Verkerk et al. (2006) | I_{Cf} | Decrease | Rat ventricular myocytes |
| Xiao et al. (2004) | I_{Cf} | Decrease | Pig ventricular myocytes |
| Guizy et al. (2005) | I_{Cf} | Decrease | HEK 293t |
| Verkerk et al. (2006) | I_{Ks} | Decrease | Pig ventricular myocytes |
| Doolan et al. (2002) | I_{Ks} | Increase (DHA) | Chinese hamster ovary cells expressing HERG |
| Verkerk et al. (2006) | I_{Ks} | Increase | Pig ventricular myocytes |
| Xiao et al. (2002) | I_{Ks} | Increase | Adult ferret cardiomyocytes |
| Verkerk et al. (2006) | I_{Ks} | Increase | Pig ventricular myocytes |
| Kim and Pleumsamran (2000) | I_{Ks} | Decrease | Unknown |
| SAC | | Unaffected | Rat atrium |

SAC, stretch activated channels; DHA, docosahexaenoic acid.
EFFECTS OF POLYUNSATURATED FATTY ACIDS IN EXPERIMENTAL MODELS OF AF

Experimental models of AF show much less variability than human populations at large. This allows the identification of specific mechanisms or substrates suitable for potential treatment with PUFAs. Models mainly based on electrical remodeling, structural remodeling, or inflammatory-related models can provide valuable insights to understand the role of n-3 PUFAs in clinical AF.

Oral supplementation with n-3 PUFAs (DHA and EPA acids), commencing 2 weeks before tachypacing onset and continuing through the fast pacing period (7 days), did not significantly affect AF duration and atrial refractory period compared to sham-operated controls in a dog model of AF where the ventricular rate was controlled by atrioventricular block and ventricular demand pacing. Further, dogs that underwent ventricular tachypacing with the same regimen of n-3 PUFAs supplementation showed decreased congestive heart failure-related atrial fibrosis and attenuated AF promotion induced by ventricular tachypacing (Sakabe et al., 2007). The authors found significantly decreased expression of phosphorylated mitogen-activated protein (MAP) kinases, which are particularly important in causing tissue fibrosis in both heart failure animals and AF patients (Goette et al., 2006; Petrich and Wang, 2004). In a dog model of AF with simultaneous fast atrial and ventricular pacing, n-3 PUFAs supplementation resulted in less conduction time heterogeneity in the left atrium, and prevented pacing-induced increase in collagen turnover and collagen deposition in atrial appendages. PUFAs reduced both AF inducibility and duration of inducible AF (Laurent et al., 2008). Echocardiographic assessment of mechanical remodeling in those animals showed a similar decrease in left atrial-emptying function in treated animals and controls (Laurent et al., 2008).

However, there are discrepancies about the effects of PUFAs in the literature that appear to be model dependent. For example, acute administration of PUFAs prevented atrial electrical remodeling by significantly reducing the shortening of atrial effective refractory period caused by several hours of fast atrial pacing in dogs (Da Cunha et al., 2007). This acute effect was not observed in the same animal model of PUFAs treatment under long-term fast atrial pacing (Sakabe et al., 2007). Interestingly, both dietary supplements and acute administration of n-3 PUFAs prevented vagally induced AF in dogs (Sarrazin et al., 2007). Experiments in vagally induced AF correlate with the relevant role of PUFAs in the cardiac cell membrane to modulate $I_{KACB}$ as described above.

The antiarrhythmic effects of PUFAs have been observed in non-tachypaced models of AF as well. Accumulating evidence indicates that inflammatory pathways are of significance in AF. Although some evidence suggests that inflammation might be a causative agent for AF (Sata et al., 2004), a substantial body of evidence supports that AF and inflammatory pathways have a bidirectional relationship (Friedrichs et al., 2011). After cardiac surgery, leukocytosis and pro-inflammatory cytokines have been directly related to the incidence of post-operative AF. As the cytokines raise, the risk of post-operative AF concomitantly increases (Ishida et al., 2006). n-3 PUFAs show anti-inflammatory effects that may prevent AF episodes related to a highly inflammatory environment. Experimentally, in a canine model of open-chest sterile pericarditis, oral PUFAs supplement for 4 weeks before the operation and 2 days afterward resulted in less AF inducibility and maintenance than in a control group under regular feeding. Before the operation, there were no significant differences in conduction time, atrial effective refractory period (AERP; defined as the longest $S_1-S_2$ coupling interval that fails to depolarize the atria) and inflammatory markers between PUFAs group and controls. Two days after surgery, C-reactive protein (CRP), IL-6, and TNF-α levels were significantly lower in the PUFAs group. PUFAs supplementation also resulted in longer AERP and shorter intra-atrial conduction time after surgery (Zhang et al., 2011).

MECHANISMS UNDERLYING AF AND THEIR LINK TO CELLULAR AND EXPERIMENTAL PUFA EFFECTS

Although the mechanisms underlying AF are not completely understood, the arrhythmia is believed to be reentrant. There is increasing evidence supporting the role of a unique or small number of functional reentrant sources (rotors) maintaining the arrhythmia (David Filgueiras Rama and José Jalife, 2011). This is largely because of the elucidation of the molecular mechanisms of reentry. Theoretically, it has been known that shortening of the action potential duration and increasing excitability can facilitate reentry (Pandit et al., 2005). However, it was not until the last decade that the role of inward rectifier K$^+$ currents, such as $I_{KACB}$ or $I_{K1}$, and their ability to increase reentrant frequency and facilitate AF became a well-established molecular mechanism responsible for AF. For a complete review on the role of inward rectifiers (see Ehrlich, 2008; Jalife, 2011). While $I_{KACB}$ may have a preferential role in paroxysmal AF and explain left-to-right differences in rates of activation (Voigt et al., 2010), the current seems to decrease in persistent AF. However, ionomic remodeling leads to an increase in $I_{K1}$ and constitutive active $I_{KACB}$ (Dobrev et al., 2001, 2005; Makary et al., 2011). Conversely, as AF becomes persistent extensive data show decrease in $I_{K1}$ or $I_{KACB}$, and the L-type Ca$^{2+}$ current (Van Waggoner et al., 1997, 1999; Dobrev et al., 2001; Sossalla et al., 2010).

While reentry seems to perpetuate the arrhythmia, Ca$^{2+}$-dependent triggered activity may initiate AF. While the spontaneous release of Ca$^{2+}$ and triggered activity implicate abnormal sarcoplasmic reticulum (SR) Ca$^{2+}$ release as a trigger, the frequency of triggered activity, and spontaneous Ca$^{2+}$ release are much slower than the typical AF activation rate (<1 vs. 6–9 Hz, respectively; Atienza et al., 2006, 2009; Voigt et al., 2012). As a result, it is unlikely they are the mechanism maintaining the arrhythmia. This idea is further supported by AF models like stretch-induced AF, in which a more depolarized resting membrane potential and the activation of SAC enable the generation of triggered activity. Even in the presence of a high rate of focal activity reentry was required to sustain AF (Filgueiras-Rama et al., 2012).

However, it is important to note that as the arrhythmia persists, electrical remodeling and functional changes in subcellular structures lead to higher susceptibility to Ca$^{2+}$-dependent triggered activity. Ryanodine (RyR2) dysfunction and SR Ca$^{2+}$ leak may contribute to further paroxysms and persistence of AF. Under certain conditions of excitability, anatomic and functional obstacles may interfere with propagation of regular or Ca$^{2+}$-dependent waves, which may cause the formation of self-sustained vortices.
Concomitantly, larger inward Na\(^+\)-Ca\(^{2+}\)-exchange current \((I_{\text{NCX}})\) for a given SR Ca\(^{2+}\) release further increase the likelihood of delayed after depolarizations and triggered activity (Voigt et al., 2012).

In addition to electrical remodeling, structural changes can facilitate the long-term maintenance of AF (Nattel et al., 2008). Structural changes include atrial dilatation and an increase in atrial fibrosis. This is a consistent finding in AF models associated with congestive heart failure (Morillo et al., 1995; Li et al., 1999). Extracellular matrix dysregulation and atrial fibrosis increases atrial conduction heterogeneity and plays an important role in stabilizing reentry and making larger areas of the atria suitable for harboring reentry. Different inter related signaling pathways appear to be involved in the development of atrial fibrosis. The most prominent pathways studied are the renin-angiotensin system (RAS), transforming growth factor-β1 (TGF-β1), and the inflammation/oxidative stress pathways (Lin and Pan, 2008). Furthermore, elevated inflammatory mediators varied according to the different sub-types of the arrhythmia. There is a graded increase in N-terminal pro-brain natriuretic peptide (NTpBNP) and TNF-α with the duration and type of AF (permanent > persistent > paroxysmal). Patients with lone AF (no overt structural heart disease) are less likely to have elevated concentrations of biomarkers (IL-10, TNF-α) compared with those with AF (Lin et al., 2010). Baseline levels of biomarkers and further decrease after cardioversion may also be used to predict sinus rhythm maintenance during the following year in patients with lone AF (Leftheriotis et al., 2009). However, structural remodeling does not occur in all AF models. Predominant electrical remodeling with minimal or no changes in atrial fibrosis are present in tachypacing induced AF models even after long periods of fast pacing, as long as tachycardiomyopathy is not present (Ausma et al., 1997).

Synthesizing all this together, the role of n-3 PUFAs in terminating AF by modulation of cardiac ion channels seems unlikely based on the limited effects observed with chronic PUFAs supplements. Moreover, once AF is initiated, the increase in \(I_{K_{1}}\) after PUFAs supplement may facilitate reentry (Verkerk et al., 2006). However, n-3 PUFAs have also been shown to prevent AF, and it is speculated that an increase in membrane fluidity and \(I_{K_{1}}\) may protect against stretch-induced triggered activity and AF initiation. Similarly, a decrease in abnormal Ca\(^{2+}\) release may also prevent focal triggered activity initiating AF (Honen and Saint, 2002). The crucial role of PUFAs to control ATP-induced increase in \(I_{K_{1}}\) channel activity may also be important in persistent AF, in which \(I_{K_{1}}\) is constitutively active. It has been proposed that the PUFAs antiarrhythmic effects lie in the ability of n-3 PUFAs to modify the atrial substrate that perpetuates the arrhythmia. Thus, PUFAs have the capability to attenuate the inflammatory cascade and adverse remodeling occurring in response to mechanical stress (Sakabe et al., 2007; Laurent et al., 2008).

**CLINICAL IMPLICATIONS OF PUFAS IN AF POPULATION**

The AF population represents a large source of variability. Therefore, specific AF subsets could benefit more than others from using n-3 PUFAs dietary supplementation. It is not surprising there are different responses to PUFAs depending on the type of AF (lone, paroxysmal, persistent, and permanent). Further, the evaluation of the efficacy of PUFAs is convoluted by concomitant therapies, degree of inflammatory biomarkers, and time-course of the supplementary dietary therapy before outcomes analysis. Based on the experimental studies we have discussed so far, we speculate that PUFAs are not predominantly antiarrhythmic ion channel blockers. Rather, they play an important role to prevent AF onset in disease states with strong inflammatory and structural remodeling components. Results from different trials highlight the potential role of n-3 PUFAs in preventing AF onset and recurrences mainly from persistent AF populations, which supports their role as upstream therapy.

The study by Calo et al. (2005) in patients who underwent coronary artery bypass graft (CABG) surgery showed that n-3 PUFAs supplementation (EPA/DHA ratio 1:2) at least 5 days before surgery reduced the incidence of post-operative AF by ≥50%. Further, it was associated with a shorter hospital stay (Calo et al., 2005). Similar results were observed in a randomized trial with the same type of surgery and same PUFAs regimen (Sorice et al., 2011). Conversely, another randomized clinical trial in patients who underwent CABG surgery did not show statistical differences between n-3 PUFAs and placebo groups (Saravanan et al., 2010). This discrepancy may be explained by different designs of the studies. The EPA/DHA supplementation ratio was 1:2 in Calo’s study and 1:2:1 in the study by Saravanan et al. (2010). Considering that DHA may have greater impact on AF prevention (Virtanen et al., 2009), the results may be somehow affected by the study design. It also should be noted that Calo’s study included AF episodes lasting >5 min compared to >30 s in Saravanans’s. This resulted in a much higher AF incidence, without a clear clinical significance of such short episodes. Finally, the use of concomitant β-blockers and statins was much lower in the study by Calo (85 and 98% compared with 57 and 56%). Optimization of these agents could have decreased the beneficial effects of n-3 PUFAs.

Two other randomized trials in patients who underwent cardiac surgery either CABG and/or valvular replacement did not show any beneficial effect of n-3 PUFAs (EPA/DHA ratio 1:2/1:4:1) in preventing post-operative AF compared to controls (Heidarsdottir et al., 2010; Farquharson et al., 2011). The study by Heidarsdottir et al. (2010) was carried out in an Icelandic population with approximately 80% of participants taking cod liver oil or other fish oils, which resulted in very small changes of plasma n-3 PUFAs concentrations after the regimen. In the second study by Farquharson et al. (2011) the results showed a trend to toward a decrease in incidence of AF in the n-3 PUFAs group. However the sample size was underestimated for the AF rates observed in the study, which resulted in no statistically significant differences. The discussed clinical studies evaluating new-onset AF following cardiac surgery are summarized in Table 2.

Beyond post-operative AF, over a 12-year follow-up period regular consumption of n-3 PUFAs (tuna and other broiled or baked fish >5 times per week) showed ≈30% lower incidence of AF among subjects older than 65 years after adjustment for other risk factors (Mozaffarian et al., 2004). Although those observational results were encouraging, subsequent randomized trials brought up controversial results. The study by Nodari et al. (2011), in patients with persistent AF and at least one relapse after cardioversion, showed significant decrease in AF recurrences after...
### Table 2 | Clinical trials in new-onset AF following cardiac surgery.

| Author                        | Year | Age (years) | Design                  | Study population | PUFAs dosage    | No of patients | Duration                        | Results                                                                 |
|-------------------------------|------|-------------|-------------------------|------------------|-----------------|----------------|---------------------------------|------------------------------------------------------------------------|
| Calo et al. (2005)            | 65.6 ± 8.5 | Open label/ randomized | Pre/post-CABG, SR | EPA/DHA 1:2 | 160 | At least 5 days before CABG until discharge | Reduced post-CABG surgical AF and shorter hospitalization |
| Saravanan et al. (2010)       | 66 (58–73) | Double blind/ randomized | Pre/post-CABG, SR | EPA/DHA 1:2.1 | 108 | At least 5 days before CABG until discharge/5 days | No reduction in AF after CABG surgery |
| Heidarsdottir et al. (2010)   | 67 (43–82) | Double blind/ randomized | Pre/post-cardiac surgery, SR | EPA/DHA 1:2.1 | 168 | 5–7 days before CABG and/or valvular repair until discharge/14 days | No reduction in AF after cardiac surgery |
| Farquharson et al. (2011)     | 64 ± 11  | Double blind/ randomized | Pre/post-cardiac surgery, SR | EPA/DHA 1:4.1 | 194 | 3 weeks before CABG and/or valve replacement until discharge/8 days | Trend to decrease in post-surgical AF. Decreased length of stay in the ICU |
| Sorice et al. (2011)          | 63 ± 10  | Open label/ randomized | Pre/post-cardiac surgery, SR | EPA/DHA 1:2 | 201 | At least 5 days before CABG until discharge | Decrease in “on-pump” CABG surgical AF |

AF, atrial fibrillation; CABG, coronary artery bypass graft surgery; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; ICU, intensive care unit; PUFA, omega-3 polyunsaturated fatty acids; SR, sinus rhythm.

### Table 3 | Main clinical trials in non-postoperative AF onset and recurrent AF.

| Author                     | Year | Age (years) | Design                  | Study population     | PUFAs Dosage     | No of patients | Duration                        | Results                                                                 |
|----------------------------|------|-------------|-------------------------|----------------------|-----------------|----------------|---------------------------------|------------------------------------------------------------------------|
| Mozaffarian et al. (2004)   | 72/65–100 | Observational prospective | Population-based | Tuna, baked fish | 4815 | 12 years | Lower incidence of AF with fish intake ≥ 1 time per week |
| Virtanen et al. (2009)      | 52.8 ± 5.3 | Observational prospective | Population-based men. SR | Fish intake | 2174 | 177 years | High serum levels of n-3 PUFAs decrease hospital diagnosis of AF |
| Kowey et al. (2010)         | 60.5 ± 12.8 | Double blind/ randomized | Symptomatic paroxysmal/persistent AF, SR | EPA/DHA 1:2.1 | 663 | 24 weeks after enrollment | No reduction in recurrent AF |
| Nodari et al. (2011)        | 69.5 ± 7 | Double blind/ randomized | Recurrent persistent AF > 1 month + ACE-I/Amiodarone | EPA/DHA 1:2.1 | 199 | 1 year | Decrease in persistent AF recurrences post-cardioversion |
| Bianconi et al. (2011)      | 69.2 ± 7.9 | Double blind/ randomized | Persistent AF > 1 month. Mainly “lone AF” | EPA/DHA 1:2 | 204 | 6 months after enrollment | No reduction in persistent AF recurrences post-cardioversion |
| Kumar et al. (2012)         | 61 ± 13  | Open label/ randomized | Persistent AF > 1 month ± ACE-I/Amiodarone/Sotalol | EPA/DHA1:2 | 178 | 1 year | Decrease in persistent AF recurrences post-cardioversion |

ACE-I, angiotensin-converting enzyme inhibitors; AF, atrial fibrillation; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; PUFA, omega-3 polyunsaturated fatty acids; SR, sinus rhythm.

Cardioversion and n-3 PUFA supplementation (EPA/DHA ratio 1.2:2). More recently, in a similar AF population, the study by Kumar et al. (2012) showed that fish oil supplementation resulted in a sixfold prolongation in the median time to AF recurrence compared to controls. Conversely, two other randomized trials by Kowey et al. (2010); Bianconi et al. (2011) did not show any beneficial effect of n-3 PUFAs in preventing AF recurrences in persistent AF patients after cardioversion or in sinus rhythm patients with previously documented AF, respectively. Again, several methodological factors may partly explain these discordant findings. Nodari’s and Kumar’s studies included patients taking n-3 PUFA supplementation for at least 4 weeks before cardioversion, with a history of at least one previous cardioversion. Nodari’s series also enrolled a population with high prevalence (≈90%) of structural heart disease. Most patients in Bianconi’s study (≈60%) were experiencing their first episode of AF and only 25% of patients had a previous cardioversion. In addition, before cardioversion, the length of n-3 PUFAs therapy was shorter than the time required for incorporation of PUFAs in the cell membrane (≈28 days). This may explain why the majority of recurrences occurred very early in follow-up (2–3 weeks), before the expected biological effects of n-3 PUFAs. In addition, in both studies with negative results the presence of structural heart disease was significantly lower than in Nodari’s study, which may represent a key factor in understanding the potential role of PUFAs in preventing structural changes preferentially in patients with significant
structural heart disease, similarly to the additional clinical benefits of spironolactone therapy in patients with AF and structural heart disease (Williams et al., 2011). The clinical studies evaluating AF incidence and recurrences are summarized in Table 3.

**FUTURE DIRECTIONS**

Data from animal studies seem to support the role of n-3 PUFAs as a therapeutic option in AF. AF models with intense structural remodeling due to heart failure and ventricular tachypacing, post open-chest surgery, and vagally induced AF have shown to benefit from n-3 PUFA supplementation. These effects are also supported by some of the effects of n-3 PUFAs at the cellular level. However, more mechanistic insights are necessary to further understand the specific pathways that make n-3 PUFAs an effective adjunctive therapy to prevent AF. Arguably, this is because structural remodeling of the atria and acute inflammation may affect AF susceptibility in a different manner based on the inflammatory pathways involved. In fact, recent data have shown that some of those inflammatory markers affect the activity of certain cardiac ion channels, as well as the interaction between cardiomyocytes and fibroblasts (Ottaviano and Yee, 2011; Ramos-Mondonрагa et al., 2011). As a result, a new experimental data is needed to understand how n-3 PUFAs influence the release of inflammatory markers and how those markers influence AF.

Changes in lipid composition of the sarcosome seem to modulate some cardiac ion currents such as IK, ICA, and at least indirectly affect membrane susceptibility to stretch (Kim and Pleumsamran, 2006; Ninio et al., 2005). Specific changes in n-3 PUFAs composition in the lipid membrane of cardiomyocytes after dietary supplementation are currently unknown and need to be addressed. It is also necessary to study the specific n-3 PUFAs effects on SACC beyond the increase in membrane compliance.

Finally, DHA and EPA seem to exert different effects at the cellular and clinical outcomes (Virtanen et al., 2009). New clinical trials based on mechanistic effects described in experimental studies will be necessary to avoid confounding factors that appear to be present in the current clinical trials.

**CONCLUSION**

Biochemical and biophysical properties of n-3 PUFAs give rise to a variety of effects at the cellular and organ levels. They include increasing cardiomyocyte membrane stability, modulation of the biophysical properties of ion channels/cellular substrata, and significant effects on the inflammatory/fibrosis signaling pathways. In light of experimental and clinical studies, the latter may be especially important in preventing AF (post-operative or clinical recurrences). Consequently, dietary supplementation of n-3 PUFAs may be considerably more beneficial in patients with pronounced structural heart disease and atrial remodeling, high levels of inflammatory biomarkers, and low baseline levels of circulating PUFAs. New ongoing clinical trials, mainly focus on AF recurrences and post-operative AF, will hopefully help to pinpoint the specific subset of AF population that will benefit most from n-3 PUFA supplementation.

**ACKNOWLEDGMENTS**

NLHBI Grant K99-HL105574 to SFN and the Alfonso Martin Escudero Foundation Grant to DFR. We thank Matt Klos for his valuable comments and suggestions during the preparation of the manuscript.

**REFERENCES**

Atienza, F., Almendral, I., Jalife, J., Zäschinger, S., Ploutz-Snyder, R., Torrecilla, E. G., Arenal, A., Kalifa, J., Fernandez-Avalos, F., and Berenfeld, O. (2009). Real-time dominant frequency mapping and ablation of dominant frequency sites in atrial fibrillation with left-to-right frequency gradients predicts long-term maintenance of sinus rhythm. *Heart Rhythm 6*, 33–40.

Atienza, F., Almendral, I., Moreno, J., Vaidyanathan, R., Talkachou, A., Kalifa, J., Arenal, A., Villacastin, J. P., Torrecilla, E. G., Sanchez, A., Ploutz-Snyder, R., Jalife, J., and Berenfeld, O. (2006). Activation of inward rectifier potassium channels accelerates atrial fibrillation in humans: evidence for a remnant mechanism. *Circulation 114*, 2434–2442.

Ausma, J., Wijffels, M., Thone, F., Wouters, L., Allelsse, M., and Borgers, M. (1997). Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. *Circulation 96*, 3157–3163.

Bianconi, L., Calo, L., Mennuni, M., Santini, L., Morosetti, P., Azzolini, P., Barbato, G., Biscione, F., Romano, P., and Santini, M. (2011). n-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicentre study. *Europe J. Cardiol.*

Blaauw, Y., Gogelein, H., Tieleman, R. G., Van Hunnik, A., Schotten, U., and Allessie, M. A. (2004). “Early” class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. *Circulation 110*, 1717–1724.

Blaustein, M. P., and Lederer, W. J. (1999). Sodium/calcium exchange: its physiological implications. *Physiol. Rev. 79*, 783–854.

Bode, F., Sachs, F., and Franz, M. R. (2001). Tarantula peptide inhibits atrial fibrillation. *Nature 409*, 35–36.

Burdge, G. (2004). Alpha-linolenic acid metabolism in men and women: nutritional and biological implications. *Curr. Opin. Clin. Nutr. Metab. Care 7*, 137–144.

Burdge, G. C., Jones, A. E., and Wootton, S. A. (2002). Eicosapentaenoic and docosapentaenoic acids are the principal products of alpha-linolenic acid metabolism in young men*. *Br. J. Nutr. 88*, 355–365.

Caldor, P. C. (2006). n-3 Polysaturatated fatty acids, inflammation, and inflammatory diseases. *Am. J. Clin. Nutr. 83*, 1505S–1519S.

Calo, L., Bianconi, L., Colivicchi, F., Lamberti, F., Lorichio, M. L., De Ruvo, E., Mee, A., Pandori, C., Staibano, M., and Santini, M. (2005). N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. *J. Am. Coll. Cardiol. 45*, 1723–1728.

Camm, A. J., Kirchhoff, P., Lip, G. Y., Schotten, U., Saveleva, I., Ernst, S., Van Gelder, I. C., Al-Attar, N., Hindricks, G., Prendergast, B., Heidusch, H., Alferi, O., Angelini, A., Atar, D., Colonna, P., De Caterina, R., De Sutter, J., Goete, Gorenek, B., Heldal, M., Holbo, S. H., Kohl, P., Le Heuzey, J. Y., Ponikowski, P., Rutter, F. H., Vahanian, A., Auricchio, A., Bax, I., Cecconi, C., Dean, V., Filippatos, G., Funck-Brentano, C., Hohls, B., Kearney, P., McDonagh, T., Popescu, B. A., Reiner, Z., Sechtem, U., Sirnes, P. A., Tendera, M., Vardas, P. E., Widimsky, A., Agladze, V., Aliot, E., Babalanski, T., Blomstrom-Lundqvist, C., Capucci, A., Crijns, H., Dahlöf, B., Foliguet, T., Glikson, M., Goethals, M., Gulda, D. C., Ho, S. Y., Klautz, R. I., Kose, S., McMurray, J., Peronne Failari, P., Raatikainen, P., Salvador, M. J., Schalji, M. I., Shekhtor, A., Sousa, J., Stepinska, J., Uetao, H., Zamorono, J. L., and Zupan, I. (2010). Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). *Europace 12*, 1360–1420.

Cappato, R., Calkins, H., Chen, S. A., Davies, W., Isakya, K., Kalman, J., Kim, Y. H., Klein, G., Natale, A., Packer, D., Skanes, A., Amborgi, F., and Biganzoli, E. (2010). Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. *Circ. Arrhythm. Electrophysiol. 3*, 32–38.

Crumb, W. J., Munfakh, N., Heck, H. A., and Harrison, L. H. Jr. (1999). Fatty acid block of the transient outward current in adult human atrium. *J. Pharmacol. Exp. Ther. 289*, 386–391.

www.frontiersin.org

September 2012 | Volume 3 | Article 370 | 7

Omega-3 PUFAs in atrial fibrillation
Da Cunha, D. N., Hamlin, R. L., Billman, G. E., and Barnes, C. A. (2007). n-3 (omega-3) polyunsaturated fatty acids prevent acute atrial electrophysiological remodeling. Br. J. Pharmacol. 150, 281–285.

David Filgueiras Rama and José Jalife. (2011). "Mechanisms underlying atrial fibrillation," in Basic Science for Clinical Electrophysiologist, ed. Charles Antzelevitch (New York: Saunders), 141–156.

Den Ruijter, H. M., Berecki, G., Verkerk, A. O., Bakker, D., Baartscheer, A., Schumacher, C. A., Belterman, C. N., De Jonge, N., Fiolet, J. W., Brouwer, I. A., and Coronel, R. (2008). Acute administration of fish oil inhibits triggered activity in isolated myocytes from rabbits and patients with heart failure. Circulation 117, S36–S44.

Dobrev, D., Carlsson, L., and Nattel, S. (2012). Novel molecular targets for atrial fibrillation therapy. Nat. Rev. Drug Discov. 11, 275–291.

Dobrev, D., Friedrich, A., Voigt, N., Jost, N., Wetter, E., Christ, T., Knaut, M., and Ravens, U. (2001). Molecular basis of downregulated G-protein-coupled inward rectifying K+ currents (I(K,ACH)) in chronic human atrial fibrillation: decrease in GIRQ4 mRNA correlates with reduced I(K,ACH) and muscarinic receptor-mediated shortening of action potentials. Circulation 104, 2531–2537.

Doolan, G. K., Panchal, R. G., Fonnes, E. L., Clarke, A. L., Williams, D. A., and Petrov, S. (2002). Fatty acid augmentation of the cardiac slowely activating delayed rectifier current (IKs) is conferred by hnnA4. PASEJ J. 16, 1662–1664.

Ehrlich, J. R. (2008). Inward rectifier potassium currents as a target for atrial fibrillation therapy. J. Cardiovasc. Electrophysiol. 19, 1155–1165.

Endres, S., Ghorbani, R., Kelley, V. E., Georgiòlis, K., Lonnemann, G., Van Der Meer, J. W. M., Cannon, J. G., Rogers, T. S., Klempner, M. S., Weber, P. C., Schaefer, E. J., Wolff, S. M., and Dinarello, C. A. (1989). The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N. Engl. J. Med. 320, 265–271.

Farquharson, A. L., Metcalfe, R. G., Sanders, P., Stuklis, R., Edwards, J. R., Gibson, R. A., Clandberg, L. G., Sullivan, T. R., James, M. J., and Young, G. D. (2011). Effect of dietary fish oil on atrial fibrillation after cardiac surgery. Am. J. Cardiol. 108, 851–856.

Filgueiras-Rama, D., Martins, R. P., Mironov, S., Yamazaki, M., Cabo, C. J., Ennis, S. R., Bandaru, K., Noutsias, S. E., Kafila, J., Benferdel, O., and Jalife, J. (2012). Chloroquine termi nates stretch-induced atrial fibrillation more effectively than flecainide in the sheep heart. Circ. Arrhythm. Electrophysiol. 5, 561–570.

Friedrichs, K., Klinek, A., and Baldus, S. (2011). Inflammatory pathways underlying atrial fibrillation. Trends Mol. Med. 17, S36–S43.

Geotte, L., Stuck, T., Rocken, C., Arndt, M., Geller, J. C., Huth, C., Ansgore, S., Klein, H. U., and Lendeckel, U. (2000). Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atrium during atrial fibrillation. J. Am. Coll. Cardiol. 35, 1669–1677.

Guizy, M., Arius, C., David, M., Gonzalez, T., and Valenzuela, C. (2005). (Omega-3) and (omega-6) polyunsaturated fatty acids block HERG channels. Am. J. Physiol. Cell Physiol. 289, C1251–C1260.

Healey, J. S., Barranchuk, A., Cristal, E., Morillo, C. A., Garfinkle, M., Yasuf, S., and Connolly, S. (2005). Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J. Am. Coll. Cardiol. 45, 1832–1839.

Heidarsdottir, R., Arnar, D. O., Skulason, S., Hafsteinsson, D., Sigfusson, J., and Ravens, U. (2010). Long-chain n-3 polyunsaturated fatty acids prevent atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 122, 877–885.

Koshiba, S., Kurata, Y., Notsu, T., Hira y, K., Kuga, T. Y., Li, P., Bahrudin, U., Harada, S., Mika, J., Yamamoto, T., Hoshikawa, T., Iga wa, O., Higaki, K., Soma, M., Yoshi da, A., Ninomiya, H., Shi ota, G., Shirayoshi, Y., and Hisatome, I. (2009). Stabilizing effects of eicosapentaenoic acid on Kv1.5 channel protein expressed in mammalian cells. Eur. J. Pharma col. 604, 93–102.

Kowey, R. P., Reifell, J. A., Ellenbo gen, K. A., Naccarelli, G. V., and Pratt, C. M. (2010). Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA 304, 2363–2372.

Kumar, S., Sutherland, F., Morton, J. B., Lee, G., Morgan, I., Wong, J., Eccleston, D. E., Voulkasen, J., Garg, M. L., and Sparks, P. B. (2012). Long-term omega-3 polyunsaturated fatty acid supplementation reduces the recurrence of persistent atrial fibrillation after electrical cardioversion. Heart 98, 323–329.

Lafuente-Laurent, C., Souto, T., Andreou, E. I., Fountoulaki, K. T., Flevari, P. G., Parisis, J. T., Panou, F. K., Andreouado, I. T., Venet suanou, K. S., Ilidromitou, E. K., and Kremasti nos, D. T. (2008). The predictive value of inflammatory and oxidative markers following the successful cardioversion of persistent lone atrial fibrillation. Int. J. Cardiol. 135, 361–369.

Leifer, W. R., Jahangiri, A., Saint, D. A., and Memchur, E. J. (2000). Effects of dietary n-3 fatty acids on contractility, Na+ and K+ currents in a rat cardiomyocyte model of arrhythmia. J. Nutr. Biochem. 11, 382–392.

Li, D., Fareh, S., Leung, T. K., and Nettle, S. (1999). Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 100, 87–95.

Li, G. R., Feng, J., Yue, L., Carrier, M., and Nattel, S. (1996). Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. Circ. Res. 78, 689–696.

Li, G. R., Sun, H. Y., Zhang, X. H., Cheng, L. C., Chiu, S. W., Tie, H. E., and Lau, C. P. (2009). Omega-3 polyunsaturated fatty acids inhibit transient outburst and ultra-rapid delayed rectifier K+ currents and Na+ current in human atrial myocytes. Cardiovasc. Res. 81, 286–293.

Li, J., Solus, J., Chen, Q., Rho, Y. H., Milne, G., Stein, C. M., and Darbar, D. (2010). Role of inflammation and oxidative stress in atrial fibrillation. Heart 96, 438–444.

Lin, C. S., and Pan, C. H. (2008). Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. Cell. Mol. Life Sci. 65, 1489–1508.

Makary, S., Voigt, N., Maguy, A., Wakili, R., Nishida, K., Harada, M., Dobrev, Omega-3 PUFAs in atrial fibrillation

Omega-3 PUFAs in atrial fibrillation

Frontiers in Physiology | Cardiac Electrophysiology

September 2012 | Volume 3 | Article 370 | 8
D, and Nattel, S. (2011). Differential protein kinase C isoform regulation and increased constitutive activity of acetylcholine-regulated potas- sium channels in atrial remodeling. Circ. Res. 109, 1031–1043.

Marchiolli, R., Barzi, F., Bomba, E., Chi- effo, C., Di Gregorio, D., Di Mascio, R., Franzosi, M. G., Geraci, E., Lev- antesi, G., Maggioni, A. P., Mantini, L., Marfisi, R. M., Mastrogiuseppe, G., Mininni, N., Nicolosi, G. L., Santini, M., Schweiger, C., Tavazza, L., Tognoni, G., Tucci, C., and Valagussa, E. (2002). Early protection against sudden death by n-3 polysaturated fatty acids in the prevention of atrial fibrillation recurrences after electro- cardiac cardioversion: a prospective, randomized study. Circulation 124, 1100–1106.

Ottaviano, F. G., and Yee, K. O. (2011). Communication signals between cardiac fibroblasts and cardiac myocytes. J. Cardiovasc. Pharmacol. 57, 513–521.

Pandit, S. V., Peter-Pyzharovska, B. A., Hoy, A. L., and McLennan, P. L. (2004). Dietary fish oil dose and time-response effects on car- diac phospholipid fatty acid compo- sition. Lipids 39, 955–961.

Pandit, S. V., Berenfeld, O., Anumonwo, J. M., Zlatkis, R. M., Kneller, J., Nat- tel, S., and Jalife, J. (2005). Ionic determinants of functional reentry in a 2-D model of human atrial cells during simulated chronic atrial fibril- lation. Biophys. J. 88, 1806–1821.

Pandit, S. V., Zlochiver, S., Filgueiras- Rama, D., Mironov, S., Yamazaki, M., Ennis, S. R., Noujaim, S. F., Workman, A. J., Berenfeld, O., Califà, E., and Jalife, J. (2011). Targeting atri- oventricular differences in ion chan- nel properties for terminating acute atrial fibrillation in pigs. Cardiovasc. Res. 89, 843–851.

Petrich, B. G., and Wang, Y. (2004). Stress-activated MAP kinases in car- diac remodeling and heart failure; new insights from transgenic stud- ies. Trends Cardiovasc. Med. 14, 50–55.

Ramos-Mondragon, R., Vega, A. V., and Avila, G. (2011). Long-term mod- ulation of Na+ and K+ currents by TGF-beta1 in neonatal rat car- diac myocytes. Pfluegers Arch. 461, 235–247.

Sakabe, M., Shintoshita-Takeshita, A., Maguy, A., Dumesnil, C., Nigam, A., Leung, T. K., and Nattel, S. (2007). Omega-3 polysaturated fatty acids prevent atrial fibrillation not associated with heart failure but not atrial tachycardia remodeling. Circu- lation 116, 2101–2109.

Sands, S. A., Reid, K. I., Windsor, S. L., and Harris, W. S. (2005). The impact of age, body mass index, and fish intake on the EPA and DHA con- tent of human erythrocytes. Lipids 40, 343–347.

Saravanan, P., Bridgewater, B., West, A. L., O’Neill, S. C., Calder, P. C., and Davidson, N. C. (2010). Omega-3 fatty acid supplementation does not reduce risk of atrial fibrilla- tion after coronary artery bypass surgery: a randomized, double- blind, placebo-controlled clinical trial. Circ. Arrhythm. Electrophysiol. 3, 46–53.

Sarmast, F., Kolli, A., Zaisert, A., Parisaian, K., Dhamoo, A. S., Guha, P. K., Warren, M., Anunomwo, J. M., Taitt, S. M., Berenfeld, O., and Jalife, J. (2003). Cholinergic atrial fibrilla- tion: IK(ACh) gradients determine unequal left/right atrial frequencies and rotor dynamics. Cardiovasc. Res. 59, 863–873.

Saarzain, J. E., Comeau, G., Daleau, P., Koninga, J., Meurisse, L., Fournier, D., and Molin, F. (2007). Reduced inci- dence of vagally induced atrial fibril- lation and expression levels of con- nexins by n-3 polysaturated fatty acids in dogs. J. Am. Coll. Cardiol. 50, 1505–1512.

Sata, N., Hamada, N., Horinouchi, T., Amatini, S., Yamashita, T., Moriyama, Y., and Miyahara, K. (2004). C4-receptor protein and atrial fibrillation. Is inflammation a con- sequence or a cause of atrial fibrilla- tion? Jpn. Heart J. 45, 441–445.

Singh, B. N., Connolly, S. J., Crijns, H. J., Roy, D., Kovay, P. R., Capuccoli, A., Radzik, D., Aliot, E. M., and Hohn- lost, S. H. (2007). Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N. Engl. J. Med. 357, 987–999.

Sorice, M., Trittio, F. P., Sordelli, C., Gregorio, R., Leung, T. K., and Nattel, S. H. (2007). Dronedarone effects on atrial fibrillation co-supplementation. Br. J. Nutr. 90, 405–412.

Van Wagoner, D. R., Pond, A. L., Lam- orgese, M., Rossie, S. S., McCarthy, P. M., and Neronne, J. M. (1999). Atrial L-type Ca2+ currents and human atrial fibrillation. Circ. Res. 85, 428–436.

Van Wagoner, D. R., Pond, A. L., McCarthy, P. M., Trimmer, I. S., and Neronne, J. M. (1997). Out- ward K+ current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation. Circ. Res. 80, 772–781.

Verkerk, A. O., Van Ginneken, A. C., Berecki, G., Den Ruijter, H. M., Schumacher, C. A., Veldkamp, M. W., Baatscheer, A., Casini, S., Opthof, T., Hovenier, R., Fiset, J. W., Zock, P. L., and Coronel, R. (2006). Incorporated sarcocemellar fish oil fatty acids shorten pig ventricular action potentials. Cardiovasc. Res. 70, 509–520.

Virtanen, J. K., Mursu, J., Voutilainen, S., and Tuomainen, T. P. (2009). Serum long-chain n-3 polysatu- rated fatty acids and risk of hospi- tal diagnosis of atrial fibrillation in men. Circulation 120, 2315–2321.

Voigt, N., Li, N., Wang, Q., Wang, W., Trafford, A. W., Abu-Taha, I., Sun, Q., Wieland, T., Ravens, U., Nattel, S., Wehrens, H. X., and Dobrev, D. (2012). Enhanced sarcolipemic reticulum Ca2+ leak and increased Na+–Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. Circula- tion 125, 2059–2070.

Voigt, N., Trausch, A., Knaat, M., Matschke, K., Varro, A., Van Wag- oner, D. R., Nattel, S., Ravens, U., and Dobrev, D. (2010). Left-to-right atrial inward rectifier potassium current gradients in patients with paroxysmal versus chronic atrial fibril- lation. Circ. Arrhythm. Electro- physiol. 3, 472–480.

Williams, R. S., Delemos, J. A., Dimas, V., Reisch, J., Hill, J. A., and Naseem, R. H. (2011). Effect of spironolac- tone on patients with atrial fibril- lation and structural heart disease. Clin. Cardiol. 34, 415–419.

Wolf, P. A., Abbott, R. D., and Kannel, W. B. (1991). Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22, 943–948.

Xiao, Y. F., Gomez, A. M., Morgan, J. P., Lederer, W. J., and Leaf, A. (1997). Suppression of voltage-gated L-type Ca2+ currents by polysatu- rated fatty acids in adult and neonatal rat ventricular myocytes.
Xiao, Y. F. Kang, J. X., Morgan, J. P., and Leaf, A. (1995). Blocking effects of polyunsaturated fatty acids on Na+ channels of neonatal rat ventricular myocytes. Proc. Natl. Acad. Sci. U.S.A. 92, 11000–11004.

Xiao, Y. F., Ke, Q., Chen, Y., Morgan, J. P., and Leaf, A. (2004). Inhibitory effect of n-3 fish oil fatty acids on cardiac Na+/Ca2+ exchange currents in HEK293t cells. Biochem. Biophys. Res. Commun. 321, 116–123.

Xiao, Y. F., Wright, S. N., Wang, G. K., Morgan, J. P., and Leaf, A. (1998). Fatty acids suppress voltage-gated Na+ currents in HEK293t cells transfected with the alpha-subunit of the human cardiac Na+ channel. Proc. Natl. Acad. Sci. U.S.A. 95, 2680–2685.

Zhang, Z., Zhang, C., Wang, H., Zhao, J., Liu, L., Lee, J., He, Y., and Zheng, Q. (2011). n-3 polyunsaturated fatty acids prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Int. J. Cardiol. 153, 14–20.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 31 May 2012; accepted: 28 August 2012; published online: 17 September 2012.

Citation: Salvador-Montañés O, Gómez-Gallanti A, Garofalo D, Noujaim SF, Peinado R and Filgueiras-Rama D (2012) Polyunsaturated fatty acids in atrial fibrillation: looking for the proper candidates. Front. Physio. 3:370. doi: 10.3389/fphys.2012.00370

This article was submitted to Frontiers in Cardiac Electrophysiology, a specialty of Frontiers in Physiology.

Copyright © 2012 Salvador-Montañés, Gómez-Gallanti, Garofalo, Noujaim, Peinado and Filgueiras-Rama. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.